This site is intended for UK healthcare professionals only
This webcast series and supporting materials were developed by the Chronic Conditions faculty in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the agenda, speaker selection, presentations or collateral content, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.
Trajenta® (linagliptin) prescribing information for the United Kingdom.
Jardiance® (empagliflozin) prescribing information for the United Kingdom.
Adverse event reporting information can be found at the bottom of this page.
Presenters: Dr Sarah Jarvis and Hannah Beba
This promotional symposium was organised and funded by Boehringer Ingelheim. On demand content for UK healthcare professionals only.
PC-GB-111022 | June 2025
TRAJENTA® (linagliptin)1 is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
JARDIANCE® (empagliflozin)2 is indicated in adults for the treatment of
insufficiently controlled T2D as an adjunct to diet and exercise:
• as monotherapy when metformin is considered inappropriate due to intolerance
• in addition to other medicinal products for the treatment of diabetes
References
1. TRAJENTA® (linagliptin) Summary of Product Characteristics
2. JARDIANCE® (empagliflozin) Summary of Product Characteristics
Trajenta® (linagliptin) prescribing information for the United Kingdom.
Jardiance® (empagliflozin) prescribing information for the United Kingdom.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).
PC-GB-111022 | June 2025
